骨髓增殖性肿瘤的预防、诊断与管理：综述系列介绍 - Suppr

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.

作者信息

Yuan Yin, Lane Steven W

机构信息

The Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, and Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.

Cancer Research Program, QIMR Berghofer Medical Research institute, Cancer Care Services, Metro North Health, Brisbane.

出版信息

Haematologica. 2025 Apr 1;110(4):825-827. doi: 10.3324/haematol.2024.285414. Epub 2025 Mar 19.

DOI:10.3324/haematol.2024.285414

PMID:40165732

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959264/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8db/11959264/97e93a5a19a0/110825.fig1.jpg

相似文献

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.

Haematologica. 2025 Apr 1;110(4):825-827. doi: 10.3324/haematol.2024.285414. Epub 2025 Mar 19.

Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH).

Curr Res Transl Med. 2023 Oct-Dec;71(4):103424. doi: 10.1016/j.retram.2023.103424. Epub 2023 Oct 20.

Introduction to a review series on classic myeloproliferative neoplasms.

Blood. 2023 Apr 20;141(16):1897-1899. doi: 10.1182/blood.2023019876.

A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.

Expert Rev Hematol. 2018 Jan;11(1):25-35. doi: 10.1080/17474086.2018.1410433. Epub 2017 Dec 2.

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?].

Harefuah. 2019 Nov;158(11):737-741.

Introduction to a review series on myeloproliferative neoplasms.

Blood. 2017 Feb 9;129(6):659. doi: 10.1182/blood-2016-12-756619. Epub 2016 Dec 27.

Practical management of the haemorrhagic complications of myeloproliferative neoplasms.

Br J Haematol. 2022 Nov;199(3):313-321. doi: 10.1111/bjh.18322. Epub 2022 Jun 20.

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

Mod Pathol. 2014 Jun;27(6):814-22. doi: 10.1038/modpathol.2013.196. Epub 2013 Nov 8.

Advances in myelodysplastic/myeloproliferative neoplasms.

Virchows Arch. 2023 Jan;482(1):69-83. doi: 10.1007/s00428-022-03465-7. Epub 2022 Dec 5.

Myeloproliferative neoplasms complicated with β-thalassemia: Two case report.

World J Clin Cases. 2022 Oct 16;10(29):10655-10662. doi: 10.12998/wjcc.v10.i29.10655.

本文引用的文献

Evolution of myeloproliferative neoplasms from normal blood stem cells.

Haematologica. 2025 Apr 1;110(4):840-849. doi: 10.3324/haematol.2023.283951. Epub 2024 Dec 5.

Pathogenesis and management of high molecular risk myeloproliferative neoplasms.

Haematologica. 2025 Apr 1;110(4):863-876. doi: 10.3324/haematol.2023.283987. Epub 2024 Dec 5.

New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?

Haematologica. 2025 Apr 1;110(4):850-862. doi: 10.3324/haematol.2023.283958. Epub 2024 Oct 24.

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.

Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.

Identifying disease-modifying potential in myelofibrosis clinical trials.

Blood. 2024 Oct 17;144(16):1679-1688. doi: 10.1182/blood.2024024220.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.

In utero origin of myelofibrosis presenting in adult monozygotic twins.

Nat Med. 2022 Jun;28(6):1207-1211. doi: 10.1038/s41591-022-01793-4. Epub 2022 May 30.

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.

Blood Adv. 2022 Apr 12;6(7):2107-2119. doi: 10.1182/bloodadvances.2021004856.

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies.

Blood Cancer J. 2021 May 17;11(5):94. doi: 10.1038/s41408-021-00480-w.

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.

Cell Stem Cell. 2021 Mar 4;28(3):514-523.e9. doi: 10.1016/j.stem.2021.02.001. Epub 2021 Feb 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.

作者信息

Yuan Yin, Lane Steven W

机构信息

The Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, and Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.

Cancer Research Program, QIMR Berghofer Medical Research institute, Cancer Care Services, Metro North Health, Brisbane.

出版信息

Haematologica. 2025 Apr 1;110(4):825-827. doi: 10.3324/haematol.2024.285414. Epub 2025 Mar 19.

DOI:10.3324/haematol.2024.285414

PMID:40165732

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959264/

Abstract

摘要

相似文献

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.

Haematologica. 2025 Apr 1;110(4):825-827. doi: 10.3324/haematol.2024.285414. Epub 2025 Mar 19.

Curr Res Transl Med. 2023 Oct-Dec;71(4):103424. doi: 10.1016/j.retram.2023.103424. Epub 2023 Oct 20.

Introduction to a review series on classic myeloproliferative neoplasms.

Blood. 2023 Apr 20;141(16):1897-1899. doi: 10.1182/blood.2023019876.

A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.

Expert Rev Hematol. 2018 Jan;11(1):25-35. doi: 10.1080/17474086.2018.1410433. Epub 2017 Dec 2.

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?].

Harefuah. 2019 Nov;158(11):737-741.

Introduction to a review series on myeloproliferative neoplasms.

Blood. 2017 Feb 9;129(6):659. doi: 10.1182/blood-2016-12-756619. Epub 2016 Dec 27.

Practical management of the haemorrhagic complications of myeloproliferative neoplasms.

Br J Haematol. 2022 Nov;199(3):313-321. doi: 10.1111/bjh.18322. Epub 2022 Jun 20.

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

Mod Pathol. 2014 Jun;27(6):814-22. doi: 10.1038/modpathol.2013.196. Epub 2013 Nov 8.

Advances in myelodysplastic/myeloproliferative neoplasms.

Virchows Arch. 2023 Jan;482(1):69-83. doi: 10.1007/s00428-022-03465-7. Epub 2022 Dec 5.

Myeloproliferative neoplasms complicated with β-thalassemia: Two case report.

World J Clin Cases. 2022 Oct 16;10(29):10655-10662. doi: 10.12998/wjcc.v10.i29.10655.

本文引用的文献

Evolution of myeloproliferative neoplasms from normal blood stem cells.

Haematologica. 2025 Apr 1;110(4):840-849. doi: 10.3324/haematol.2023.283951. Epub 2024 Dec 5.

Pathogenesis and management of high molecular risk myeloproliferative neoplasms.

Haematologica. 2025 Apr 1;110(4):863-876. doi: 10.3324/haematol.2023.283987. Epub 2024 Dec 5.

New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?

Haematologica. 2025 Apr 1;110(4):850-862. doi: 10.3324/haematol.2023.283958. Epub 2024 Oct 24.

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.

Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.

Identifying disease-modifying potential in myelofibrosis clinical trials.

Blood. 2024 Oct 17;144(16):1679-1688. doi: 10.1182/blood.2024024220.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.

In utero origin of myelofibrosis presenting in adult monozygotic twins.

Nat Med. 2022 Jun;28(6):1207-1211. doi: 10.1038/s41591-022-01793-4. Epub 2022 May 30.

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.

Blood Adv. 2022 Apr 12;6(7):2107-2119. doi: 10.1182/bloodadvances.2021004856.

Blood Cancer J. 2021 May 17;11(5):94. doi: 10.1038/s41408-021-00480-w.

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.

Cell Stem Cell. 2021 Mar 4;28(3):514-523.e9. doi: 10.1016/j.stem.2021.02.001. Epub 2021 Feb 22.

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series.

作者信息

机构信息

出版信息

相似文献

本文引用的文献